Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells

IntroductionThe c-Jun coactivator, Jun activation-domain binding protein 1 (Jab1) also known as the fifth component of the COP9 signalosome complex (CSN5), is a novel candidate oncogene whose aberrant expression contributes to the progression of breast carcinoma and other human cancers. The mechanism of Jab1 gene expression and its deregulation in cancer cells remains to be identified. We therefore investigated the transcriptional regulatory mechanisms of Jab1 expression in human breast carcinoma cells.MethodsTo identify potential regulators of Jab1 transcription, we cloned the 5' upstream region of the human Jab1 gene and mapped its transcriptional start site. We identified binding sequences for the CCAAT/enhancer binding protein (C/EBP) and GATA, as well as a signal transducer and activator of transcription-3 (Stat3) consensus sequence overlapping the C/EBP site, using 5'- deletion analysis and a gene reporter assay. Mutational analysis of these binding sites was performed to confirm their roles in promoting Jab1 transcription in breast cancer cells. We further confirmed these binding sites using electrophoretic mobility shift assays (EMSAs) and chromatin immunoprecipitation (ChIP) assays. We also analyzed whether the siRNA-mediated inactivation of Stat3 and Src could reduce Jab1-promoter activity and whether interleukine-6 (IL-6) could mediate increased Jab1 expression through Stat3 signaling.ResultsWe identified binding sequences for C/EBP, GATA, as well as a Stat3 consensus sequence overlapping the C/EBP site in the promoter region of Jab1. C/EBP-beta2 is a potential transcriptional activator of Jab1 and mutation of the C/EBP/Stat3 binding site significantly reduced Jab1-promoter activity. In addition, inhibiting Stat3 significantly reduced Jab1-promoter activation. EMSA and ChIP assays confirmed that C/EBP, GATA1 and Stat3 bind to Jab1 promoter in breast carcinoma cells. We also found that Src, an activator of Stat3, is involved in Jab1-promoter activation. siRNA knockdown of Src reduced the Jab1-promoter activity, similar to the results seen when Stat3 was inhibited in breast carcinoma cells. Interestingly, reactivation of Stat3 in normal mammary epithelial cells (MCF-10A, MCF-10F) is sufficient to reactivate Jab1 expression. Treatment with the cytokine IL-6 resulted in increased Jab1 expression that was blocked by inhibition of Stat3.ConclusionsThese findings reveal a novel mechanism of Jab1 gene regulation and provide functional and mechanistic links between the Src/Stat3 and IL-6/Stat3 signaling axes that are involved in the activation of Jab1 transcription and regulation of this novel oncogenic protein.

[1]  G. Mills,et al.  Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[2]  T. Hoey,et al.  Cooperative DNA Binding and Sequence-Selective Recognition Conferred by the STAT Amino-Terminal Domain , 1996, Science.

[3]  K. Nakashiro,et al.  Skp2 and Jab1 Expression Are Associated with Inverse Expression of p27KIP1 and Poor Prognosis in Oral Squamous Cell Carcinomas , 2003, Oncology.

[4]  Y. M. Lee,et al.  Jab1 interacts directly with HIF-1alpha and regulates its stability. , 2002, The Journal of biological chemistry.

[5]  Hideaki Nakajima,et al.  Signal Transducers and Activators of Transcription 3 Augments the Transcriptional Activity of CCAAT/Enhancer-binding Protein α in Granulocyte Colony-stimulating Factor Signaling Pathway* , 2005, Journal of Biological Chemistry.

[6]  F. Claret,et al.  JAB1/CSN5: a new player in cell cycle control and cancer , 2010, Cell Division.

[7]  W. Zundel,et al.  The Emerging Role of the COP9 Signalosome in Cancer , 2005, Molecular Cancer Research.

[8]  T. Toda,et al.  A new group of conserved coactivators that increase the specificity of AP-1 transcription factors , 1996, Nature.

[9]  Allard Kaptein,et al.  Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction (*) , 1996, The Journal of Biological Chemistry.

[10]  D. Chamovitz,et al.  JAB1/CSN5 and the COP9 signalosome , 2001, EMBO reports.

[11]  J. Crispino,et al.  GATA1 in normal and malignant hematopoiesis. , 2005, Seminars in cell & developmental biology.

[12]  T. McDonnell,et al.  Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. Giardina,et al.  Cytoplasmic Phospholipase A2 Levels Correlate with Apoptosis in Human Colon Tumorigenesis , 2005, Clinical Cancer Research.

[14]  Y. M. Lee,et al.  Jab1 Interacts Directly with HIF-1α and Regulates Its Stability* , 2002, The Journal of Biological Chemistry.

[15]  L. Aravind,et al.  Role of Predicted Metalloprotease Motif of Jab1/Csn5 in Cleavage of Nedd8 from Cul1 , 2002, Science.

[16]  C. Zahnow,et al.  CCAAT/enhancer-binding protein β: its role in breast cancer and associations with receptor tyrosine kinases , 2009, Expert Reviews in Molecular Medicine.

[17]  C. Schwechheimer,et al.  COP9 signalosome revisited: a novel mediator of protein degradation. , 2001, Trends in cell biology.

[18]  T. Yeatman,et al.  Role of Src expression and activation in human cancer , 2000, Oncogene.

[19]  C. Kittas,et al.  Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). , 2003, Cancer research.

[20]  C. Clevenger Roles and regulation of stat family transcription factors in human breast cancer. , 2004, The American journal of pathology.

[21]  T. McDonnell,et al.  Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma , 2003 .

[22]  Howard Y. Chang,et al.  Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.

[23]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[24]  Xing Wang Deng,et al.  The COP9 signalosome. , 2003, Annual review of cell and developmental biology.

[25]  J. Darnell,et al.  A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. , 1995, Genes & development.

[26]  S. Burley,et al.  RNA polymerase II transcription initiation: a structural view. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Kraft,et al.  COP9 signalosome‐specific phosphorylation targets p53 to degradation by the ubiquitin system , 2001, The EMBO journal.

[28]  Yasuo Watanabe,et al.  Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[30]  D. Ramji,et al.  CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.

[31]  B. Aggarwal,et al.  Targeting Signal‐Transducer‐and‐Activator‐of‐Transcription‐3 for Prevention and Therapy of Cancer , 2006, Annals of the New York Academy of Sciences.

[32]  L. Bundy,et al.  CCAAT/enhancer binding protein beta (C/EBPβ)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture , 2003, Oncogene.

[33]  C. Zahnow CCAAT/enhancer binding proteins in normal mammary development and breast cancer , 2002, Breast Cancer Research.

[34]  E. Eaton,et al.  Characterization of C/EBPbeta isoforms in normal versus neoplastic mammary epithelial cells. , 2001, Journal of cellular physiology.

[35]  Han-Woong Lee,et al.  Jab1 Induces the Cytoplasmic Localization and Degradation of p53 in Coordination with Hdm2* , 2006, Journal of Biological Chemistry.

[36]  S. Rane,et al.  IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled , 2000, Oncogene.

[37]  J. Kaptein,et al.  Anti-IgM-mediated Regulation of c-myc and Its Possible Relationship to Apoptosis* , 1996, The Journal of Biological Chemistry.

[38]  Howard Y. Chang,et al.  CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. , 2008, Cancer research.

[39]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[40]  J. Rosen,et al.  The role of C/EBPbeta in mammary gland development and breast cancer. , 2003, Journal of mammary gland biology and neoplasia.

[41]  E. Eaton,et al.  Characterization of C/EBPβ isoforms in normal versus neoplastic mammary epithelial cells , 2001 .

[42]  W. Hung,et al.  HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. , 2007, Endocrine-related cancer.

[43]  Xuesong Cao,et al.  Jab1 antagonizes TGF‐β signaling by inducing Smad4 degradation , 2002 .

[44]  Y. Dong,et al.  Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  Yalei Wu,et al.  Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. , 2002, EMBO reports.

[46]  X. Deng,et al.  The COP9 signalosome: more than a protease. , 2008, Trends in biochemical sciences.

[47]  Jason A. Lowry,et al.  GATA-1: one protein, many partners. , 2006, The international journal of biochemistry & cell biology.

[48]  M. Loda,et al.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.